These FFAs lead to hypertriglyceridemia by inhibiting lipoprotein lipase in adipose and muscle tissues, in addition to increased production of very-low-density lipoprotein (VLDL) and TG in the liver. The gene discussed is LPL; the disease is hypertriglyceridemia.